Rotavirus VP4 Antigen Engineering for Stable Subunit Vaccines
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for rotavirus are not safe, effective, or inexpensive, and existing recombinant expressions of rotavirus neutralization antigens like VP4 are unstable and difficult to produce in pure, homogeneous forms.
Innovation Solution
Development of structure-based vaccine design using high-resolution structural data of rotavirus VP4 to engineer stable polypeptides, such as VP5* and VP8*, which are incorporated into subunit vaccines, and integrated with DNA- or vector-based immunization strategies to enhance safety and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a live, oral vaccine against rotavirus is used, then immunization effectiveness is improved, but safety deteriorates due to temporal association with intestinal intussusception
Solution Approach 1:
The patent extracts only the essential immunogenic components (VP4 neutralization antigens) from the complete rotavirus structure to create a subunit vaccine. This extraction approach maintains immunization effectiveness while eliminating the harmful effects associated with live virus vaccines, specifically the risk of intestinal intussusception.
Solution Approach 2:
The patent creates recombinant copies of the VP4 neutralization antigens through genetic engineering. These recombinant protein copies replicate the immunogenic properties of the natural virus antigens without possessing the pathogenic characteristics, thereby providing safety while maintaining effectiveness.
2Object-affected harmful factors
If recombinant expressions of rotavirus neutralization antigens are produced, then vaccine safety is improved, but manufacturing complexity increases due to instability and difficulty in producing pure, homogeneous forms
Solution Approach 1:
The patent focuses on producing specific structural domains (VP5* and VP8* fragments) with defined local properties rather than attempting to produce the entire VP4 protein. This localized production approach simplifies manufacturing by targeting only the essential neutralization epitopes, thereby achieving purity and homogeneity while reducing overall complexity.
Solution Approach 2:
The patent employs structure-based molecular engineering to optimize the physical and chemical parameters of the recombinant antigens. By modifying amino acid sequences and structural characteristics based on high-resolution structural data, the patent enhances protein stability and facilitates homogeneous production, thereby reducing manufacturing complexity.
3Reliability
If structure-based molecular engineering is applied, then vaccine efficacy is improved through reliable presentation of neutralization determinants, but development time increases
Solution Approach 1:
The patent utilizes high-resolution structural data of VP4 antigens obtained through preliminary structural studies to guide the molecular engineering process. This preliminary structural information allows for rational design of stable immunogens with optimized neutralization epitope presentation, thereby improving efficacy while streamlining the development process by avoiding trial-and-error approaches.
Data Source
AI summary
The present invention relates to novel recombinant polypeptide antigens that may comprise subunit vaccines against rotavirus infection. Further, the present invention relates to methods for use of said antigens in the diagnosis, treatment and prevention of rotavirus infection.